NASDAQ:XBIO

Xenetic Biosciences Q2 2025 Earnings Results & Report

Xenetic Biosciences logo
$1.40 -0.14 (-9.09%)
Closing price 11/20/2026 03:47 PM Eastern
Extended Trading
$1.46 +0.06 (+3.93%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xenetic Biosciences beat analyst expectations on both earnings and revenue in its Q2 2025 results, released August 12, 2025. The company reported EPS of -$0.45 versus the -$0.64 consensus estimate, while revenue of $590 thousand topped the $482 thousand estimate by $108.00 thousand.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Xenetic Biosciences EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.64
Beat/Miss
Beat by +$0.19
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Xenetic Biosciences Revenue Results

Actual Revenue
$590 thousand
Expected Revenue
$482 thousand
Beat/Miss
Beat by +$108.00 thousand
YoY Revenue Growth
N/A

Xenetic Biosciences Q2 2025 Earnings FAQ

Xenetic Biosciences (NASDAQ:XBIO) reported earnings of -$0.45 per share for Q2 2025, beating the consensus estimate of -$0.64. The report was announced on Tuesday, August 12, 2025.

Xenetic Biosciences reported revenue of $590 thousand for Q2 2025, against a consensus estimate of $482 thousand.

Xenetic Biosciences Earnings Headlines

Contrasting Xenetic Biosciences (XBIO) and Its Peers
Prediction: NVDA will “snap back” on this date
Others paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.tc pixel
See More Xenetic Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email.

About Xenetic Biosciences

Xenetic Biosciences (NASDAQ:XBIO) is a biotechnology company focused on developing immuno-oncology treatments. Its XCART platform is designed to create personalized CAR T-cell therapies that recognize tumor-specific antigens on B-cell lymphomas, with the goal of targeting cancer cells while limiting effects on healthy cells.

The company’s earlier work included PolyXen, a drug-delivery platform based on polysialic acid that was designed to extend the time biologic medicines remain in the body. Xenetic’s current stated focus is advancing its XCART technology and related product candidates.

View Xenetic Biosciences Profile